Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Assets (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Assets for 16 consecutive years, with $18.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets rose 167.56% to $18.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.7 million, a 167.56% increase, with the full-year FY2024 number at $6.6 million, down 41.75% from a year prior.
  • Assets was $18.7 million for Q3 2025 at Plus Therapeutics, up from $10.4 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $24.8 million in Q3 2021 to a low of $5.6 million in Q1 2024.
  • A 5-year average of $15.7 million and a median of $14.9 million in 2023 define the central range for Assets.
  • Peak YoY movement for Assets: crashed 64.06% in 2024, then soared 167.56% in 2025.
  • Plus Therapeutics' Assets stood at $24.8 million in 2021, then fell by 3.57% to $23.9 million in 2022, then tumbled by 52.29% to $11.4 million in 2023, then plummeted by 41.75% to $6.6 million in 2024, then skyrocketed by 181.47% to $18.7 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Assets are $18.7 million (Q3 2025), $10.4 million (Q2 2025), and $12.1 million (Q1 2025).